Tolerability profile of metformin/glibenclamide combination tablets (Glucovance®): A new treatment for the management of type 2 diabetes mellitus

Drug Safety

Volumn 27, Issue 15, 2004, Pages 1205-1216

  Davidson, Jaime A ^a   Scheen, André J ^b   Hewlett, Harry C S ^c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c CardioMetabolic Care   (France)

^d Harrier House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; METFORMIN; SULFONYLUREA;

ABDOMINAL PAIN; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DIET THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTIC ACIDOSIS; LOW DRUG DOSE; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; VOMITING;

BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; GLYBURIDE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; METFORMIN; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 11244256740     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427150-00004     Document Type: Review

References (41)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12
4. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-30
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 Suppl. 1: S15-35
6. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2002 update [online]. Available from URL: http://www.aace.com/clin/guidelines/ diabetes_2002.pdf [Accessed 2004 Jan 4]
7. Turner RC, Cull CA, Frighi V, et al. Glycaemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12
8. Veehof L, Stewart R, Haaijer-Ruskamp F, et al. The development of polypharmacy: a longitudinal study. Fam Pract 2000; 17: 261-7
9. Leichter SB, Thomas S. Combination medications in diabetes care: an opportunity that merits more attention. Clin Diabetes 2003; 21: 175-8
10. Hewlett H, Porte F, Allavoine T, et al. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin 2003; 19: 218-25
11. Dailey GE. Glyburide/metformin tablets: a new therapeutic option for the management of type 2 diabetes. Exp Opin Pharmacother 2003; 4: 1417-30
12. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-41
13. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002; 4: 201-8
14. Garber A, Donovan D, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3598-604
15. Blonde L, Rosenstock J, Mooradian AD, et al. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 2002; 4: 368-75
16. Marre M, Hewlett H, Lehert P, et al. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002; 19: 673-80
17. Dailey GE, Noor MA, Park JS, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004; 116: 223-9
18. tc response [abstract]. Diabetes Res Clin Pract 2000; 50 Suppl. 1: P265
19. Bailey CJ. Antidiabetic drugs. Br J Cardiol 2000; 7: 350-60
20. Garber A, Marre M, Blonde L, et al. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance®) in type 2 diabetes. Diabetes Obes Metab 2003; 5: 171-9
21. Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. Clin Ther 2002; 24: 1401-13
22. Dailey GE, Mohideen P, Fiedorek FT. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. Clin Ther 2002; 24: 1426-38
23. Blonde L, Rosenstock J, Piper BA, et al. Durable antidiabetic effect of glyburide/metformin tablets as second-line therapy for type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 2: A106
24. Eschwège E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab 2003; 29: 6S19-27
25. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103:491-7
26. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994; 11: 953-60
27. Stenman S, Melander A, Groop PH, et al. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-72
28. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003; 25: 890-903
29. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995; 333: 541-9
30. Gregorio F, Ambrosi F, Manfrini S, et al. Poorly controlled elderly type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med 1999; 16: 1016-24
31. Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 16: 828-34
32. Moses R, Carter J, Slobodniuk R, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-24
33. Marre M, Van Gaal L, Usadel KH, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002; 4: 177-86
34. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994; 17: 1100-9
35. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-5
36. Tosi F, Muggeo M, Brun E, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism 2003; 52: 862-7
37. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 2003; 27: 147-61
38. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30: 197-228
39. Lalau J-D, Race J-M. Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999; 20: 377-84
40. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-71
41. Cryer R, Mills D, Henry DH, et al. Comparative outcomes study of metformin intervention versus conventional approach: The COSMIC Approach Study [abstract]. Diabetes 2003; 52 Suppl. 1: A115